Genome-wide association study of late-onset myasthenia gravis: Confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations

Molecular Medicine

Volumn 21, Issue , 2015, Pages 769-781

  Seldin, Michael F ^a   Alkhairy, Omar K ^b   Lee, Annette T ^c   Lamb, Janine A ^d   Sussman, Jon ^e   Pirskanen Matell, Ritva ^b   Piehl, Fredrik ^b   Verschuuren, Jan J G M ^f   Kostera Pruszczyk, Anna ^g   Szczudlik, Piotr ^g   McKee, David ^e   Maniaol, Angelina H ^h   Harbo, Hanne F ⁱ   Lie, Benedicte A ⁱ   Melms, Arthur ^j,k   Garchon, Henri Jean ^l   Willcox, Nicholas ^m   Gregersen, Peter K ^c   Hammarstrom, Lennart ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Greater Manchester Neurosciences Centre   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^m UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; HLA A ANTIGEN; HLA ANTIGEN; HLA DQA1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DQA1 GENE; EPIGENETICS; FEMALE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HLA A GENE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOLECULAR PATHOLOGY; MYASTHENIA GRAVIS; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TNFRSF11A GENE; ZBTB10 GENE;

EID: 84975152216     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2015.00232     Document Type: Article

References (65)

1. McGrogan A, Sneddon S, de Vries CS. (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 34:171-83.
2. Meriggioli MN, Sanders DB. (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet. 8:475-90.
3. Carr AS, Cardwell CR, McCarron PO, McConville J. (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 10:46.
4. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 26:1054-9.
5. Chuang WY, et al. (2014) Late-onset myasthenia gravis-CTLA4(low) genotype association and low-for-age thymic output of naive T cells. J. Autoimmun. 52:122-9.
6. Maniaol AH, et al. (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One. 7:e36603.
7. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 103:579-601.
8. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J. Am. Geriatr. Soc. 48:1442-8.
9. Akaishi T, et al. (2014) Insights into the classification of myasthenia gravis. PLoS One. 9:e106757.
10. Janer M, et al. (1999) A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum. Immunol. 60:909-17.
11. Avidan N, Le Panse R, Berrih-Aknin S, Miller A. (2014) Genetic basis of myasthenia gravis: a comprehensive review. J. Autoimmun. 52:146-53.
12. Giraud M, et al. (2001) Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 57:1555-60.
13. Grob D, Brunner N, Namba T, Pagala M. (2008) Lifetime course of myasthenia gravis. Muscle Nerve. 37:141-9.
14. Vandiedonck C, et al. (2006) Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59:404-7.
15. Gregersen PK, et al. (2012) Risk for myasthenia gravis maps to a (151) Pro—>Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 72:927-935.
16. Renton AE, et al. (2015) A genome-wide association study of myasthenia gravis. JAMA Neurol. 72:396-404.
17. Purcell S, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559-75.
18. Pritchard JK, Stephens M, Donnelly P. (2000) Inference of population structure using multilocus genotype data. Genetics. 155:945-59.
19. Falush D, Stephens M, Pritchard JK. (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics. 164:1567-87.
20. Kosoy R, et al. (2009) Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum. Mutat. 30:69-78.
21. Price AL, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38:904-9.
22. O’Connell J, et al. (2014) A general approach for haplotype phasing across the full spectrum of relatedness. PLoS Genet. 10:e1004234.
23. Fuchsberger C, Abecasis GR, Hinds DA. (2014) minimac2: faster genotype imputation. Bioinformatics. 31:782-4.
24. Howie BN, Donnelly P, Marchini J. (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5:e1000529.
25. Jia X, et al. (2013) Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One. 8:e64683.
26. Browning BL, Browning SR. (2009) A unified approach to genotype imputation and haplotypephase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84:210-23.
27. Boyle AP, et al. (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22:1790-7.
28. Pruim RJ, et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 26:2336-7.
29. Degner JF, et al. (2012) DNase I sensitivity QTLs are a major determinant of human expression variation. Nature. 482:390-4.
30. Coviello AD, et al. (2012) A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation. PLoS Genet. 8:e1002805.
31. Ferreira MA, et al. (2014) Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. J. Allergy Clin. Immunol. 133:1564-71.
32. Eriksson N, et al. (2012) Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One. 7:e34442.
33. Paternoster L, et al. (2011) Meta-analysis of genomewide association studies identifies three new risk loci for atopic dermatitis. Nat. Genet. 44:187-92.
34. Hinds DA, et al. (2013) A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. Nat. Genet. 45:907-11.
35. Tillotson LG. (1999) RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter. J. Biol. Chem. 274:8123-8.
36. Li X, et al. (2010) MicroRNA-27a indirectly regulates estrogen receptor α expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology. 151:2462-73.
37. Tone M, Powell MJ, Tone Y, Thompson SA, Waldmann H. (2000) IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J. Immunol. 165:286-91.
38. Tone M, Tone Y, Babik JM, Lin CY, Waldmann H. (2002) The role of Sp1 and NF-kappa B in regulating CD40 gene expression. J. Biol. Chem. 277:8890-7.
39. Bynote KK, et al. (2008) Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 9:137-52.
40. Rubtsova K, Marrack P, Rubtsov AV. (2015) Sexual dimorphism in autoimmunity. J. Clin. Invest. 125:2187-93.
41. Kaya GA, et al. (2014) The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey. PLoS One. 9:e104760.
42. Bottini N, et al. (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36:337-8.
43. Begovich AB, et al. (2004) A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330-7.
44. Kyogoku C, et al. (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75:504-7.
45. Bottini N, Peterson EJ. (2014) Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Ann. Rev. Immunol. 32:83-119.
46. Hughes AE, et al. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24:45-8.
47. Guerrini MM, et al. (2008) Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83:64-76.
48. Albagha OM, et al. (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat. Genet. 42:520-4.
49. Estrada K, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44:491-501.
50. Roberts NA, et al. (2012) Rank signaling links the development of invariant gammadelta T cell progenitors and Aire(+) medullary epithelium. Immunity. 36:427-37.
51. Anderson DM, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175-9.
52. Dougall WC, et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-24.
53. Mewar D, et al. (2006) Haplotype-specific gene expression profiles in a telomeric major histocompatibility complex gene cluster and susceptibility to autoimmune diseases. Genes Immun. 7:625-31.
54. Noble JA, et al. (2010) HLA class I and genetic susceptibility to type 1 diabetes: results from the type 1 Diabetes Genetics Consortium. Diabetes. 59:2972-9.
55. Raychaudhuri S, et al. (2012) Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44:291-6.
56. Jawaheer D, et al. (2002) Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am. J. Hum. Genet. 71:585-94.
57. Morris DL, et al. (2012) Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am. J. Hum. Genet. 91:778-93.
58. Quinones-Lombrana A, et al. (2008) BAT1 promoter polymorphism is associated with rheumatoid arthritis susceptibility. J. Rheumatol. 35:741-4.
59. Gockel I, et al. (2014) Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nat. Genet. 46:901-4.
60. McMichael AJ, Gotch FM, Santos-Aguado J, Strominger JL. (1988) Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:9194-8.
61. Tackenberg B, et al. (2007) Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. Eur. J. Immunol. 37:849-63.
62. Selmi C, Brunetta E, Raimondo MG, Meroni PL. (2012) The X chromosome and the sex ratio of autoimmunity. Autoimmun. Rev. 11:A531-7.
63. Padua L, et al. (2000) SFEMG in ocular myasthenia gravis diagnosis. Clin. Neurophysiol. 111:1203-7.
64. Farrugia ME, Jacob S, Sarrigiannis PG, Kennett RP. (2009) Correlating extent of neuromuscular instability with acetylcholine receptor antibodies. Muscle Nerve. 39:489-93.
65. Witoonpanich R, Dejthevaporn C, Sriphrapradang A, Pulkes T. (2011) Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin. Neurophysiol. 122:1873-7.